-
Sector Analysis
Systemic Sclerosis (SSc): Epidemiology Report and Forecast to 2035
Systemic sclerosis (SSc) is a rare, chronic autoimmune connective-tissue disease characterized by small-vessel vasculopathy, immune dysregulation, and excessive collagen deposition causing fibrosis of the skin and internal organs (Genetic and Rare Disease Information Center, 2026; Hughes et al., 2020; Mayo Clinic, 2024). The precise cause of SSc is unknown, and the disease likely results from genetic susceptibility interacting with environmental or occupational exposures, such as respirable crystalline silica and certain organic solvents (Osman, Aldien and Netchiporouk, 2026). SSc has three...
-
Product Insights
Lupus Nephritis: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Lupus Nephritis - Global Clinical Trials Review, 2026" provides an overview of Lupus Nephritis Clinical trials scenario. This report provides top line data relating to the clinical trials on Lupus Nephritis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Sicca Syndrome (Sjogren): Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Sicca Syndrome (Sjogren) - Global Clinical Trials Review, 2026" provides an overview of Sicca Syndrome (Sjogren) Clinical trials scenario. This report provides top line data relating to the clinical trials on Sicca Syndrome (Sjogren). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Sector Analysis
Myasthenia Gravis Market Opportunity Assessment, Epidemiology, Treatment, Clinical Trials, Unmet Needs and Forecast to 2034
This report covers the 7 major markets and provides an Excel-based forecast model for the Myasthenia Gravis market through 2034. The MG market across the 7MM was valued at $4.5 billion in 2024 and is expected to grow to $13.0 billion by 2034 at a compound annual growth rate (CAGR) of 11.1%. The US represents the largest market for MG, with roughly 75.4% of sales across the seven major markets (7MM)—the US, France, Germany, Italy, Spain, the UK, and Japan—in...
-
Sector Analysis
Graft versus Host Disease (GvHD): Epidemiology Report and Forecast to 2035
Graft-versus-host disease (GvHD) is a common and potentially serious complication that occurs after allogeneic hematopoietic stem cell transplantation (HSCT). HSCT is used as a potential cure for hematological cancers, syndromes of bone marrow failure, and congenital disorders of the hematopoietic system (Hymes, Alousi and Cowen, 2012; Passweg et al., 2025). GvHD occurs when the donor stem cells or the graft attack healthy cells in the patient or the host (Blood Cancer United, 2024). GvHD can damage a patient’s tissues and...
-
Product Insights
Psoriasis: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Psoriasis - Global Clinical Trials Review, 2026" provides an overview of Psoriasis Clinical trials scenario. This report provides top line data relating to the clinical trials on Psoriasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Systemic Lupus Erythematosus - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Systemic Lupus Erythematosus - Global Clinical Trials Review, 2026" provides an overview of Systemic Lupus Erythematosus Clinical trials scenario. This report provides top line data relating to the clinical trials on Systemic Lupus Erythematosus. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Sector Analysis
Systemic Lupus Erythematosus and Lupus Nephritis Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034
This report covers the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends. Key topics covered include a strategic competitive assessment of current and future drugs, unmet needs, KOL insights, and implications for the Systemic Lupus Erythematosus and Lupus Nephritis market. The base year of the sales forecast model is 2024, and the forecast period...
-
Product Insights
Plaque Psoriasis (Psoriasis Vulgaris) - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Plaque Psoriasis (Psoriasis Vulgaris) - Global Clinical Trials Review, 2026" provides an overview of Plaque Psoriasis (Psoriasis Vulgaris) Clinical trials scenario. This report provides top line data relating to the clinical trials on Plaque Psoriasis (Psoriasis Vulgaris). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Rheumatoid Arthritis - Global Clinical Trials Review, 2026
Understand the Global Clinical Trials Landscape for Rheumatoid Arthritis Rheumatoid arthritis remains a key focus area in global clinical research, with ongoing trials shaping the future of treatment and innovation. This report provides a comprehensive snapshot of the global clinical trials landscape, covering trial activity across regions, countries (G7 & E7), phases, statuses, endpoints, and sponsor types. As a result, you gain a clear understanding of where research is accelerating and how the competitive landscape is evolving. Report Value Proposition...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.